These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15508300)

  • 1. [Aminoglycosides to critically ill patients].
    Heslet L; Tvede M; Schierbeck J
    Ugeskr Laeger; 2004 Oct; 166(42):3733. PubMed ID: 15508300
    [No Abstract]   [Full Text] [Related]  

  • 2. [Aminoglycosides to critically ill patients--and others].
    Frimodt-Møller N
    Ugeskr Laeger; 2004 Nov; 166(49):4496; author reply 4497. PubMed ID: 15626110
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aminoglycosides to critically ill patients: altera pars et audiatur].
    Schønheyder HC; Freundlich M; Pedersen G; West H; Thomsen RW
    Ugeskr Laeger; 2004 Nov; 166(49):4494-6. PubMed ID: 15626109
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of Pseudomonas aeruginosa infection in critically ill patients.
    Grossi P; Dalla Gasperina D
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):639-62. PubMed ID: 17009943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure.
    Hayes D; Kanga JF; Anstead MI; Kuhn RJ
    Pediatr Pulmonol; 2008 May; 43(5):511-3. PubMed ID: 18383117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent trend of infection caused by Pseudomonas aeruginosa in patients with hematologic disorders].
    Funada H
    Nihon Rinsho; 1991 Oct; 49(10):2381-6. PubMed ID: 1721098
    [No Abstract]   [Full Text] [Related]  

  • 7. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
    Marsot A; Hraiech S; Cassir N; Daviet F; Parzy G; Blin O; Papazian L; Guilhaumou R
    Int J Antimicrob Agents; 2020 Oct; 56(4):106124. PubMed ID: 32739478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.
    Rahal JJ
    Clin Infect Dis; 2006 Sep; 43 Suppl 2():S95-9. PubMed ID: 16894522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.
    Cotta MO; Gowen B; Truloff N; Bursle E; McWhinney B; Ungerer JP; Roberts JA; Lipman J
    Infect Dis (Lond); 2015; 47(10):739-42. PubMed ID: 25753768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of antibiotics in sepsis].
    Scheel O; Bevanger L; Viggen B
    Tidsskr Nor Laegeforen; 2004 Sep; 124(18):2397. PubMed ID: 15467815
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of Pseudomonas infections and antibiotics.
    Norrby R
    Scand J Infect Dis Suppl; 1981; 29():81-6. PubMed ID: 6274001
    [No Abstract]   [Full Text] [Related]  

  • 12. Shrimp (Penaeus monodon) anti-lipopolysaccharide factor reduces the lethality of Pseudomonas aeruginosa sepsis in mice.
    Pan CY; Chao TT; Chen JC; Chen JY; Liu WC; Lin CH; Kuo CM
    Int Immunopharmacol; 2007 May; 7(5):687-700. PubMed ID: 17386416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of antibiotics. Aminoglycosides.
    Noone P
    Br Med J; 1978 Aug; 2(6137):613-4. PubMed ID: 698616
    [No Abstract]   [Full Text] [Related]  

  • 14. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
    Obritsch MD; Fish DN; MacLaren R; Jung R
    Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecthyma gangrenosum: a rare manifestation of Pseudomonas aeruginosa sepsis in a critically ill adult patient.
    Frantzeskaki F; Betrosian AP
    Eur J Dermatol; 2008; 18(3):345-6. PubMed ID: 18474472
    [No Abstract]   [Full Text] [Related]  

  • 16. [Simplified and not exact about antibiotics].
    Simonsen GS; Berdal JE; Sundsfjord A; Berild D
    Tidsskr Nor Laegeforen; 2004 Sep; 124(18):2397; author reply 2397-8. PubMed ID: 15467814
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination therapy versus monotherapy for Pseudomonas aeruginosa bacteremia.
    Bross JE
    Am J Med; 1991 Jan; 90(1):135. PubMed ID: 1986585
    [No Abstract]   [Full Text] [Related]  

  • 18. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
    Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
    Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas bacteremia. Retrospective analysis of 410 episodes.
    Bodey GP; Jadeja L; Elting L
    Arch Intern Med; 1985 Sep; 145(9):1621-9. PubMed ID: 3927867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Refractory respiratory tract infections. 4. Selection of chemotherapeutic agents and their administration. c. Pseudomonas infections].
    Oizumi K
    Nihon Rinsho; 1987 Mar; 45(3):526-30. PubMed ID: 3298728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.